teriflunomide
Sign in to saveTeriflunomide, sold under the brand name Aubagio, is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive. However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide." The drug was approved for use in the United S
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470602409
- Drug.image
- Teriflunomide_structure.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Teriflunomide 3D ball.png
- Drug.image_class2
- bg-transparent
- Drug.alt2
- Ball-and-stick model of the teriflunomide molecule
- Drug.tradename
- Aubagio
- Drug.MedlinePlus
- a613010
- Drug.DailyMedID
- Teriflunomide
- Drug.pregnancy_AU
- X
- Drug.pregnancy_category
- Contraindicated
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AK02
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
via Wikipedia infobox
Article
4 sectionsContents
- Adverse effects
- Mechanisms of action
- Activation of leflunomide to teriflunomide
- References
Teriflunomide, sold under the brand name Aubagio, is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive. However, the subsequent TENERE head-to-head comparison trial reported that "although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a, relapses were more common with teriflunomide." The drug was approved for use in the United States in September 2012 and for use in the European Union in August 2013.
==Adverse effects==
Connections
Categories
3-Hydroxypropenals4-(Trifluoromethyl)phenyl compoundsAnilidesConjugated nitrilesCYP1A2 inducersDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs with non-standard legal statusECHA InfoCard ID from WikidataHuman drug metabolitesImmunosuppressantsSanofi